Equity Overview
Price & Market Data
Price: $1.35
Daily Change: -$0.12 / 8.89%
Daily Range: $1.33 - $1.52
Market Cap: $162,838,608
Daily Volume: 3,363,115
Performance Metrics
1 Week: -15.19%
1 Month: -28.72%
3 Months: 173.5%
6 Months: 135.5%
1 Year: -27.57%
YTD: -2.90%
Company Details
Employees: 105
Sector: Health technology
Industry: Biotechnology
Country:
Details
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.